(Q42528609)

1 November 2017

Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

1 November 2017

1 reference

1 reference

1 reference

1

1 reference

1 November 2017

Giuseppe Morgante

2

0 references

Antonio Cianci

object named as

Antonio Cianci

4

0 references

Vincenzo De Leo

object named as

Vincenzo De Leo

6

0 references

Felice Petraglia

object named as

Felice Petraglia

5

0 references

author name string

Marco Palumbo

3

1 reference

PubMed ID

12477517

1 November 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

1 November 2017

Fertility and Sterility

1 reference

1 November 2017

78

1 reference

1 November 2017

6

1 reference

1 November 2017

1234-1239

1 reference

Hypersecretion of luteinizing hormone and the polycystic ovary syndrome

1 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Pathogenesis and treatment of polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

The Impact of Insulin Secretion on the Ovarian Response to Exogenous Gonadotropins in Polycystic Ovary Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

Insulin-like growth factor-I regulates aromatase activity in human granulosa and granulosa luteal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904346-7

10.1016/S0015-0282(02)04346-7

7 January 2021

Identifiers

DOI

1 reference

1 November 2017

1 reference

PubMed ID

12477517